Clever Leaves Holdings Inc.

CLVR

CA1867602031

Pharmaceuticals

Delayed Nasdaq Other stock markets 11:17:52 2024-05-01 am EDT			5-day change	1st Jan Change
1.56 ^USD	-0.32%		-60.31%	-25.52%

Apr. 29	Top Midday Decliners	MT
Apr. 29	North American Morning Briefing : Investors Brace for This Week's Earnings, Fed Decision	DJ

Clever Leaves Holdings Inc. Provides Earnings Guidance for the Year 2023

March 30, 2023 at 04:34 pm EDT

Clever Leaves Holdings Inc. provided earnings guidance for the year 2023. For the year, the company expects full year 2023 revenue to range between $19 million and $22 million.

Latest news about Clever Leaves Holdings Inc.

Top Midday Decliners	Apr. 29	MT
North American Morning Briefing : Investors Brace for This Week's Earnings, Fed Decision	Apr. 29	DJ
Clever Leaves to Delist Securities From Nasdaq	Apr. 26	MT
Clever Leaves Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Clever Leaves Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Earnings Flash (CLVR) CLEVER LEAVES Reports Q4 Revenue $4.6M	Apr. 01	MT
An unknown buyer acquired Portuguese farm assets of Clever Leaves Holdings Inc. for $1.5 million.	Mar. 31	CI
KAC Investments LLC acquired Herbal Brands, Inc. from Clever Leaves Holdings Inc. for $8 million.	Mar. 26	CI
Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia	Feb. 13	CI
Transcript : Clever Leaves Holdings Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (CLVR) CLEVER LEAVES Reports Q3 Revenue $3.8M, vs. Street Est of $5.2M	Nov. 09	MT
Clever Leaves Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Clever Leaves Holdings Inc. Revises Revenue Guidance for the Full Year 2023	Nov. 09	CI
Transcript : Clever Leaves Holdings Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Earnings Flash (CLVR) CLEVER LEAVES Reports Q2 Revenue $5M, vs. Street Est of $5M	23-08-14	MT
Clever Leaves Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Clever Leaves Holdings Inc. Reiterates Earnings Guidance for the Year 2023	23-08-14	CI
Clever Leaf Holdings Inc. Announces Colombian Flower Is Now Available to Australian Patients Through Strategic Partnership with Australian Natural Therapeutics Group	23-07-26	CI
Clever Leaves Holdings Inc.(NasdaqCM:CLVR) dropped from Russell 3000E Value Index	23-06-23	CI
Clever Leaves Holdings Inc.(NasdaqCM:CLVR) dropped from Russell 3000E Index	23-06-23	CI
Clever Leaves Holdings Inc.(NasdaqCM:CLVR) dropped from Russell Microcap Index	23-06-23	CI
Clever Leaves Holdings Inc.(NasdaqCM:CLVR) dropped from Russell Microcap Value Index	23-06-23	CI
Clever Leaves Holdings Inc. and Astrasana Holding AG Partner to Establish International Supply Agreement for Medical Cannabis Extracts in Czech Republic and Switzerland	23-05-30	CI
Clever Leaves Partners with Somaí Pharmaceuticals and Sends First Commercial Shipments to Portugal	23-05-25	CI
Clever Leaves Holdings Inc. Receives Brazilian GMP Certification for Cannabis Products by ANVISA	23-05-16	CI

Chart Clever Leaves Holdings Inc.

Duration

Period

More charts

Clever Leaves Holdings Inc. is a multinational operator and licensed producer of pharmaceutical-grade cannabinoids. The Company's segments include Cannabinoid and Non-Cannabinoid. The Cannabinoid segment is comprised of cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products. The Non-Cannabinoid operating segment is comprised of the brands and manufacturing assets acquired as part of its acquisition of Herbal Brands. The Non-Cannabinoid segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing wellness products and nutraceuticals, excluding cannabinoid products. Its customers for the Herbal Brands products include specialty and health retailers, mass retailers and specialty and health stores in the United States. It offers product portfolio in two categories: nutraceuticals and cannabinoids. The nutraceutical products consist of a variety of beverage and powder products.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.565

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
CLEVER LEAVES HOLDINGS INC.	-25.52%	2.75M
DONG-E-E-JIAO CO.,LTD.	+39.33%	6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.38%	4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.17%	3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.98%	3.16B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.41%	2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+48.74%	1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.82%	1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.24%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.96%	1.6B

Alternative Medicine